Femasys receives AMA CPT Editorial Panel approval for new CPT code

Femasys (FEMY) announced that it has received notice from the American Medical Association, AMA, CPT Editorial Panel approving a new Category III Current Procedural Terminology, CPT, code covering the use of FemaSeed for intratubal insemination, ITI, a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to this first-step infertility treatment option. “The creation of a new Category III code for the FemaSeed ITI procedure reflects the innovation and differentiated approach of our technology,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “As we initiate the rollout of FemaSeed to gynecologists and their clinical teams, supported by the availability of our FemSperm product line, we intend to expand our provider footprint, accelerate adoption, and increase access to care for more than 10 million women in the U.S. affected by infertility. Together, these offerings advance our scalable commercialization strategy and position us for sustainable long-term growth.”